Administration of estradiol-17j7 (E) to ovariectomized (ovx) sheep results in the synthesis and release of an M, 90 000-92 000 glycoprotein into the oviductal lumen and into culture medium of ampullar explants (Biol Reprod 1992; 47:889-902). The objective of this study was to determine when and from what region of the oviduct the Mr 90 000-92 000 glycoprotein is synthesized and released during early pregnancy. Estrous ewes were bred to intact rams of known fertility, and oviducts were obtained at estrus (Day 0) and at Days 1.5, 2, 3, 4, 6, and 16 of pregnancy. Pregnancy was verified by the presence of a fertilized egg or developing conceptus and a functional corpus luteum. Oviductal secretions were collected by flushing oviducts with saline and by explant culture. The oviductal fimbria, ampulla, and isthmus were individually cultured (24 h) in the presence of 5 H-leucine (3H-leu) or H-glucosamine (H-glcN). The presence of the Mr 90 000-92 000 glycoprotein in oviductal flushings and culture medium was determined by fluorography and Western blotting. The Mr 90 000-92 000 protein was present in SDS gels and blots of oviductal flushings from animals through Days 4-6 of pregnancy, but not in flushings from Day 16 pregnant animals or from ovx, untreated animals. This protein was present in H-leu-and 'H-glcN-labeled culture medium of the oviductal ampulla (Days 0, 1.5, 2, 3, 4, 6, and 16) and fimbria (Days 0, 1.5, 2, 3, and 4) during early pregnancy. The M, 90 000-92 000 protein was not detected in oviductal ampulla or fimbria culture medium obtained from ovx animals, nor was it present in culture medium of the isthmus oviduct obtained from estrous and pregnant animals. These data show that the E-dependent Mr 90 000-92 000 glycoprotein is synthesized and released by the oviduct in a temporally and regionally specific manner during early pregnancy as the gametes and fertilized egg are traversing the tube and prior to a systemic rise in progesterone.
INTRODUCTION
In mammals, fertilization and early embryonic cleavage take place in the estrogen (E)-dominated oviduct. The fertilized egg leaves the oviduct and enters the uterus, at approximately Day 3 of pregnancy, concurrently with a rise in systemic progesterone (P) and a decline in E levels. The epithelial lining of the oviduct is sensitive to ovarian hormone fluctuations that occur during the estrous or menstrual cycle and pregnancy. A morphological gradient of ovarian steroid responsiveness in the fimbria, ampulla, and isthmus regions of the primate oviduct has been reported [1] . In the macaque, the effects of E and P on the differentiation-dedifferentiation of oviductal epithelial cells are very pronounced in the fimbria, less so in the ampulla, and least in the isthmus. Recently we have shown that in the sheep, E induces the synthesis and release of an Mr 90 000-92 000 glycoprotein from the ampulla but not the isthmus of the oviduct, indicating that biosynthetic gradients of steroid responsiveness also exist [2] .
Steroid-modulated oviductal secretory proteins have been identified in several species [2] [3] [4] [5] [6] . These proteins share several common features, including induction by E and repression by P, localization to the nonciliated epithelial cells, a relatively high molecular weight, and glycosylation. In the sheep [2] and pig [51, the major E-induced glycoproteins are synthesized and released only by the ampulla oviduct. In the baboon [7] , sheep [8, 9] , hamster [10] , and mouse [11] , E-dependent oviductal glycoproteins contribute to the extracellular matrix of the embryo by associating with the zona pellucida and to the exclusive microenvironment of the embryo by entering the perivitelline space. Data from co-culture experiments [12] [13] [14] and isolated oviduct culture systems [15, 16] strongly suggest that oviductal secretions enhance in vitro fertilization rates and embryonic development. In the pregnant animal, these reproductive processes take place in the ampulla oviduct.
Using steroid-treated ovariectomized (ovx) animals, we have shown that the sheep oviduct undergoes region-specific biosynthetic changes in response to E and P [2] . The ampulla oviduct synthesizes and releases an E-dependent Mr 90 000-92 000 glycoprotein packaged in secretory granules in the nonciliated epithelial cells. This protein is produced exclusively by that region of the oviduct where fertilization and embryonic development take place. The isthmus oviduct, the site of sperm storage, does not synthesize and release this protein. Sutton et al. [17] have shown that the Mr 90 000-92 000 glycoprotein is present in oviductal flushings obtained from ewes at estrus and until Day 3 of the estrous cycle. Fractions of oviductal flushings containing this protein bind sperm [18] . In early cleavage-stage sheep embryos, the Mr 90 000-92 000 glycoprotein local-izes to the zona pellucida and perivitelline space [8, 9] . Our hypothesis is that in the sheep, the Mr 90 000-92 000 glycoprotein is synthesized and released from the E-differentiated ampulla oviduct during the first few days of pregnancy as the gametes are traversing the tube; there it associates with the egg and sperm to facilitate fertilization and embryonic development. These biosynthetic changes would occur prior to a systemic rise in serum P levels, i.e., prior to the time the fertilized egg leaves the oviduct and enters the uterus at Day 3-4 of pregnancy.
In the present study, oviducts were obtained from ewes at estrus and at specific stages of pregnancy. The presence of the Mr 90 000-92 000 glycoprotein in oviductal secretions was determined through two procedures: collection of oviductal flushings representing in vivo secretions from all segments of the oviduct, and collection of in vitro secretions via explant culture that distinguished the secretory activities of the fimbria, ampulla, and isthmus oviduct. The objective of the study was to determine when and from which region of the oviduct the Mr 90 000-92 000 glycoprotein is synthesized and released during early pregnancy in the ewe.
MATERIALS AND METHODS

Reagents
Tissue culture supplies were purchased from Gibco Laboratories, Grand Island, NY. L- [1- 3 H]Leucine ( 3 H-leu; specific activity 60 Ci/mmol) and D- [6- 3 H]glucosamine ( 3 H-glcN; specific activity 42.5 Ci/mmol) were from ICN Radiochemicals (Irvine, CA). Electrophoresis supplies were purchased from Bio-Rad Laboratories (Richmond, CA). XAR-5 film was from Eastman-Kodak (Rochester, NY). Progesterone, 173-estradiol, and PMSF were from Sigma Chemical Co. (St. Louis, MO). Immobilin was from Millipore Corp. (Bedford, MA). Lutalyse was purchased from UpJohn Vet. Products (Kalamazoo, MI). All other chemicals of reagent grade or better were purchased from Sigma.
Animals and Tissue Collection
Sexually mature Florida native ewes exhibiting at least two normal estrous cycles were used in these studies. All tissues were collected in the month of November during the fall breeding season. Ewes were observed twice daily for estrous behavior following i.m. treatment with 10 mg Lutalyse. Ewes were bred to intact rams of known fertility on the first day of standing estrus (Day 0) and 12 and 24 h later. The reproductive tract was aseptically removed at the time of hysterectomy from Day 0, 1.5, 2, 3, 4, 6, and 16 pregnant ewes. Estrus and Days 1.5, 2, and 3 of pregnancy were selected because this is the time when ovulation, fertilization, and embryonic development take place in the oviduct. Days 4, 6, and 16 were selected because nidatory P levels are rising at this time and the fertilized egg has left the oviduct to reside in the uterus. After Day 3 of pregnancy, the E-differentiated oviduct has completed its role in guaranteeing reproductive success and, under the influence of P, is dedifferentiating. Pregnancy was verified by the presence of a functional corpus luteum and a fertilized egg or developing conceptus. Oviductal tissue was obtained at the time of hysterectomy from three animals at each stage of pregnancy. Oviductal flushings and tissue obtained from long-term (4-6 wk) ovx animals (n = 3), where E and P are not detected in the systemic circulation, were used as a standard for comparison of steroid-regulated, pregnancy-related changes in the synthesis and release of the Mr 90 000-92 000 glycoprotein. Oviductal flushings and oviductal tissue were also obtained from three ovx animals treated with one 4-cm E implant. The serum steroid levels produced by an E implant (E -5-10 pg/ml) have been shown to be within the physiological range observed during estrus and to induce the synthesis and release of the Mr 90 000-92 000 glycoprotein [2] .
Collection and Analysis of In Vivo Oviductal Secretions
In vivo oviductal secretions were collected by flushing oviducts with 0.9% saline. Sterile saline (6 ml) was gently introduced into the oviduct at the uterotubal junction and recovered at the ostium of the oviduct. To determine whether the presence of a fertilized egg affected the release of the E-dependent Mr 90 000-92 000 glycoprotein, flushings obtained from oviducts ipsilateral and contralateral to the corpus luteum were individually analyzed. Flushings were immediately placed on ice and PMSF was added to a final concentration of 10 mM; flushings were centrifuged (5000 x g, 20 min), dialyzed extensively against distilled water at 4°C (molecular weight cutoff 12 000-14 000), and stored at -20°C. The presence of the Mr 90 000-92 000 protein in oviductal flushings was determined by 10% SDS gels and Western blotting using a specific rabbit polyclonal antiserum to the Mr 90 000-92 000 glycoprotein. Protein concentration in dialyzed flushings was determined by the method of Bradford [19] .
Collection and Analysis of In Vitro Oviductal Secretions
In vitro oviductal secretions were collected by means of explant culture. To determine whether the fertilized egg affected the synthesis and release of the Mr 90 000-92 000 glycoprotein, oviducts ipsilateral and contralateral to the corpus luteum were explant-cultured. For explant culture, flushed oviducts were trimmed of mesentery, and the fimbria, ampulla, and isthmus oviduct were individually cultured in Earle's modified Eagle's Minimal Essential Medium (150 mg tissue/6 ml medium) according to the procedure of Basha et al. [20] . Newly synthesized and released Mr 90 000-92 000 protein was detected by the addition of concentration of unlabeled leucine and glucose in the culture medium was reduced 10-fold. After 24 h of culture, the medium was placed on ice and PMSF was added to a final 10 mM concentration; culture medium was centrifuged (5000 x g, 20 min), dialyzed extensively against 10 mM Tris, pH 8.3 (molecular weight cutoff 12 000-14 000), and stored at -20°C. The synthesis and release of the Mr 90 000-92 000 protein was detected in culture medium by 10% SDS gel followed by fluorography and Western blotting using a specific rabbit polyclonal antiserum to the Mr 90 000-92 000 glycoprotein [2] . The specificity of this antiserum for the Mr 90 000-92 000 glycoprotein has been confirmed in a previous study [2] . Radioactivity in dialyzed culture medium was determined by scintillation spectrometry; protein concentration, by the method of Bradford [19] .
Electrophoresis and Immunoblotting
The proteins present in explant culture medium (37 500 cpm) and oviductal flushings (30 ,ug) were separated on 10% SDS gels according to the procedure of Laemmli [21] . Radiolabeled proteins in culture medium were detected in fluorographs of dried gels. Before gels were dried, they were soaked (15 min, room temperature [RT]) in 1 M sodium salicylate as a fluoroenhancer. Dried gels were exposed to XAR-5 film at -70 0 C. For Western blotting, proteins (30 Ipg) present in oviductal flushings and explant culture medium were separated on 10% SDS gels and electrophoretically transferred [22] to Immobilon (overnight, RT) in a buffer containing 0.027 M NaH 2 PO 4 , 0.126 M Na 2 HPO 4 , 25% (v/v) methanol, and 0.05% (w/v) SDS. For immunostaining of blots, all antibodies were diluted in PBS (pH 7.0) containing 3% (w/v) BSA. Blots were blocked in 5% (w/v) nonfat dry milk in PBS (pH 7.0; 30 min, RT), incubated in either immune or preimmune serum (2 h, RT) diluted 1:750, and then incubated in goat anti-rabbit IgG conjugated to horseradish peroxidase (HRP; 2 h, RT) diluted 1:2000. Antigenantibody complexes were detected by incubation in 0.003 M 4-chloro-l-napthol in PBS (pH 7.0) containing 0.0175% H 2 0 2 . The reaction was stopped by placing blots in distilled water.
RESULTS
In Vivo Secretion of the Mr 90 000-92 000 Protein: Oviductal Flushings
The presence of the Mr 90 000-92 000 protein in in vivo oviductal secretions, collected by flushing oviducts in estrous and pregnant animals, was determined by SDS-PAGE and Western blotting ( Figs. 1 and 2) . For animals at Days 1.5, 2, 3, 4, and 6 of pregnancy, flushings that contained the fertilized egg (i.e., those from the ipsilateral oviduct) were analyzed separately from flushings collected from the contralateral oviduct. Since a fertilized egg is not present in oviducts at Day 0 (estrus) and Day 16 of pregnancy, the ipsilateral and contralateral oviductal flushings from Day 0 and Day 16 were pooled prior to analysis. The Mr 90 000-92 000 glycoprotein was detected in Coomassie Blue-stained gels of flushings collected on Day 0 (estrus) and on Days 1.5, 2, and 3 of pregnancy; it was barely visible in gels of flushings obtained on Days 4 and 6 and was not detected in gels from Day 16 pregnant animals (Fig. 1) . Western blots of oviductal flushings were incubated in immune (Fig. 2) and preimmune serum. The production and specificity of the antiserum have previously been described [2] . When Western blots of oviductal flushings obtained from pregnant animals were stained with immune serum, the Mr 90 000-92 000 glycoprotein was detected in ipsilateral and contralateral oviductal flushings until Day 6 of pregnancy (Fig. 2) . Prior to Day 4 of pregnancy, no apparent difference in the relative amount of the Mr 90 000-92 000 protein could be detected in blots of ipsilateral and contralateral flushings; however, oviductal flushings containing the fertilized egg collected at Day 4 of pregnancy appeared to contain less of the Mr 90 000-92 000 protein than did flushings collected from the contralateral oviduct. Reaction product was considerably reduced in oviductal luminal flushings from Day 6 of pregnancy, and was not detected in SDS gels or Western blots incubated in immune serum in flushings from Day 16 (Fig. 2) . The protein detected in flushings from pregnant animals had a diffuse banding pattern similar to the pattern we have reported for E-treated ovx animals [2] . Consistent with our previous findings [2] , this protein was not detected in SDS gels or Western blots incubated in immune serum of flushings from untreated ovx animals or in sheep serum (Fig. 2) . When blots of oviductal flush proteins were incubated in preimmune serum, no specific reaction product was detected (data not shown).
FIG. 2. Representative Western blots (30
In Vitro Secretion of the Mr 90 000-92 000 Protein: Explant Culture Medium
Ampulla oviduct. Culture medium of the ampulla oviduct from pregnant animals was separated on 10% SDS gels, and the synthesis and release of the Mr 90 000-92 000 glycoprotein was detected by fluorography of dried gels (Fig.  3) and Western blotting of electrophoretically separated proteins (Fig. 4) . Since no differences in the in vitro synthesis and release of the Mr 90 000-92 000 glycoprotein were observed from oviducts ipsilateral or contralateral to the corpus luteum, only data for culture medium from ipsilateral oviducts are shown. Figure 3 shows representative fluorographs of 3 H-leu- (Fig. 3A) and 3 H-glcN- (Fig. 3B ) labeled culture medium proteins obtained from animals at Days 0, 1.5, 2, 3, 4, 6, and 16 of pregnancy as compared with those from untreated ovx animals and ovx animals treated with E for 6 days. The Mr 90 000-92 000 protein was detected in fluorographs of 3 H-leu-labeled culture medium from animals at Days 0, 1.5, 2, 3, 4, 6, and 16 of pregnancy; however, its labeling intensity was reduced in explant culture medium of ampulla oviducts from Day 4, 6, and 16 pregnant ewes. The glycoprotein was detected in 3 H-glcNlabeled culture medium at Days 0, 1.5, 2, and 3 of pregnancy, corresponding to the time of intense 3 H-leu incorporation. When Western blots of ampulla culture medium were incubated in immune serum, the Mr 90 000-92 000 glycoprotein was detected in 3 H-leu-and 3 H-glcN-labeled culture medium derived from pregnant animals and ovx animals treated with E for 6 days, but not from untreated ovx animals (Fig. 4) . No immunoreactivity was observed in blots incubated in preimmune serum (data not shown).
Fimbria oviduct. The synthesis and release of the Mr 90 000-92 000 protein was detected by fluorography of dried gels (Fig. 5 ) and Western blotting (Fig. 6 ) in the culture medium of the fimbria oviduct from pregnant animals. No differences in the synthesis and release of the Mr 90 000-92 000 glycoprotein were detected in segments of the fimbria oviduct ipsilateral or contralateral to the corpus luteum. Figures 5 and 6 represent data obtained from the ipsilateral fimbria oviduct. of pregnancy as compared to untreated ovx animals and ovx animals treated with E for 6 days. The labeling intensity of the Mr 90 000-92 000 protein was enhanced in the 3 Hleu-labeled culture medium from Days 0, 1.5, 2, 3, and 4 of pregnancy. The Mr 90 000-92 000 protein was detected in fluorographs of 3 H-glcN-labeled culture medium from animals at Days 0, 1.5, and, to a lesser extent, Day 2 of pregnancy as compared to ovx untreated controls. When blots of 3 H-leu or 3 H-glcN culture medium were incubated in immune serum, the Mr 90 000-92 000 protein was detected at Days 0, 1.5, and 2 of pregnancy (Fig. 6) . Immune serum recognized a protein doublet at Day 0; it recognized a single-molecular-weight protein (Mr 92 000) at Days 1.5 and 2 of pregnancy and in fimbria culture medium from ovx animals treated with E for 6 days. The protein did not have the characteristic diffuse banding pattern seen in Western blots of oviductal flushings (Fig. 2) and ampulla oviduct culture medium (Fig. 4) . The Mr 90 000-92 000 glycopro- Fig. 3) . Refer to Figure  1 for explanation of abbreviations.
tein was not detected in fluorographs or Western blots of culture medium from the fimbria of untreated ovx animals. When blots were incubated in preimmune serum, no specific reaction product was observed (data not shown).
Isthmus oviduct. The M, 90 000-92 000 glycoprotein was not detected in fluorographs or Western blots of 3 Hleu-or 3 H-glcN-labeled culture medium (data not shown). This is consistent with our previous data, which showed that the Mr 90 000-92 000 glycoprotein was not synthesized and released by isthmus oviducts obtained from ovx E-and P-treated animals [2] .
DISCUSSION
As we have previously shown, an Mr 90 000-92 000 glycoprotein is synthesized and released from the nonciliated cells of the oviduct into lumen and ampulla oviduct explant cultures from ovx ewes treated with physiological levels of E [2] . The data presented in the current study show that the E-dependent Mr 90 000-92 000 glycoprotein is synthesized and released by the oviduct in a temporally and regionally specific manner during early pregnancy at the time the fertilized egg is traversing the tube and prior to a systemic rise in serum P levels. The Mr 90 000-92 000 protein was present in in vivo oviductal secretions at estrus and until approximately Day 4 of pregnancy, corresponding to the period of intense synthesis and release of the glycoprotein by ampulla and fimbria explant cultures. This glycoprotein was not detected in the explant culture medium of the isthmus oviduct at estrus or during early pregnancy. The steroid-regulated, regional secretory specialization of the sheep oviduct during the first few days of pregnancy further substantiates the concept of unique segmental roles of the tube in reproduction.
At approximately Day 3 of pregnancy in the sheep, P levels rise to -1.5-3 ng/ml, with E levels declining as the embryo leaves the oviduct and enters the uterus. The Edependent Mr 90 000-92 000 glycoprotein was detected in SDS gels and Western blots of oviductal flushings obtained at estrus and until Days 4-6 of pregnancy. No difference in the amount of the glycoprotein was observed in flushings containing the fertilized egg and the contralateral flush until Day 4, when the amount was reduced in flushings obtained from the oviduct that had contained the cleaving embryo. This difference was not due to variations in the biosynthesis of the E-dependent protein, since the ipsilateral (Fig. 3 ) and contralateral (data not shown) oviducts synthesized and released similar amounts of the radiolabeled protein in vitro. Association and potential uptake of Immune serum recognized the M, 90 000-92 000 protein in culture medium of fimbria oviducts obtained from estrous (dO) and pregnant (d1.5 and 2) animals (arrows), not from ovx animals. Note the absence of a diffuse staining pattern observed in blots of the ampulla oviduct culture medium (Fig. 4) . Included for comparison is culture medium of the ampulla oviduct obtained from an estrous animal (Amp dO) with the M, 90 000-92 000 protein indicated by the arrow. Refer to Figure 1 for explanation of abbreviations.
the Mr 90 000-92 000 glycoprotein by the zona pellucida and blastomere membranes of the sheep embryo [8, 9] could account for the observed decrease in oviducts ipsilateral to the corpus luteum. The data provided here show that the Mr 90 000-92 000 glycoprotein was released into the oviductal lumen at estrus and until approximately Day 4 of pregnancy to form part of the biochemical environment in which fertilization and embryonic development occur. After Day 3 of pregnancy, the embryo enters the uterus and the oviduct has completed its role in the reproductive process; thus, release of the Mr 90 000-92 000 protein would no longer be necessary.
Ampulla oviduct explants obtained from estrous and pregnant ewes synthesized and released the Mr 90 000-92 000 protein. The intensity of 3 H-leu-labeled protein was reduced after Day 4 of pregnancy (Fig. 3) and 3 H-glcN was incorporated into the Mr 90 000-92 000 protein until Day 3 (Fig. 3) , a time identical to that when P levels are rising and when the Mr 90 000-92 000 protein was detected in in vivo oviductal secretions (Figs. 1 and 2 ). The importance of carbohydrate moieties for glycoprotein secretion and biological function has been described [23, 24] . Chilton et al. [25] have shown that ovarian steroids regulate the activity of enzymes involved in the attachment of 0-and N-linked oligosaccharide chains to proteins in the rabbit endocervix. A similar phenomenon may be occurring in the oviduct so that an antiestrogenic effect of nidatory P is to modify the activity of enzymes involved in the glycosylation of steroidregulated oviductal secretory proteins. This may explain why the Mr 90 000-92 000 glycoprotein was absent in the in vivo secretions and why 3 H-glcN was no longer incorporated into protein after Day 3 of pregnancy. The nonglycosylated form of the Mr 90 000-92 000 protein detected in 3 H-leu-labeled explant culture medium after Day 3 of pregnancy could result from spillage into the surrounding medium due to the lack of in vivo regulatory mechanisms (including P) that would otherwise prevent its release. In addition, since the Mr 90 000-92 000 protein was detected in Western blots of ampulla oviduct culture medium at all stages of pregnancy studied, these data also suggest that the antibody recognizes the protein, not the carbohydrate portion of the molecule.
The fimbria oviduct synthesized and released the Mr 90 000-92 000 protein at estrus and during the first few days of pregnancy; however, the temporal pattern differed from that in the ampulla oviduct. Fluorographs of fimbria culture medium indicated that the protein was synthesized and released from explants until Day 3-4 in 3 H-leu-labeled culture medium and Day 1.5 in 3 H-glcN-labeled medium. In the macaque, light and electron microscopy have shown that the antagonist effects of P are most pronounced in the fimbria, less so in the ampulla [1] . Our data show that in the sheep, a biosynthetic gradient of ovarian steroid responsiveness occurs whereby the fimbria is more sensitive than the ampulla to the antiestrogenic effects of P in terms of the synthesis of the Mr 90 000-92 000 glycoprotein. In the fimbria, as in the ampulla, incorporation of 3 H-glcN into the Mr 90 000-92 000 protein ceased prior (-0.5-2 days) to that of 3 H-leu, implying a potentially similar effect of P on glycosylation of the protein in the fimbria. In Western blots of fimbria culture medium, the Mr 90 000-92 000 protein was characterized by distinct protein bands vastly different from the broad diffuse band observed in fluorographs of fimbria and ampulla culture medium as well as in Western blots of ampulla oviduct culture medium and oviductal flushings. The antibody used in our studies was made to the ampulla oviduct protein. The fimbria oviduct may synthesize and release a protein similar, but not identical, to that of the ampulla oviduct, so that our antiserum may have recognized a portion of the fimbria glycoprotein that has epitopes common to the ampulla-derived protein.
We have been unable to immunocytochemically localize the Mr 90 000-92 000 protein in sections of the fimbria oviduct using our antiserum (Murray and Nobriega, unpublished data). The relationship, if any, between the Mr 90 000-92 000 ampulla oviduct protein and the protein synthesized and released by the fimbria oviduct is not known. Studies are underway to determine whether these are two proteins, varying in protein backbone, or one protein with varying post-translational modifications including glycosylation, phosphorylation, and sulfation. The sheep oviduct may synthesize and release two subtly different proteins with complementary effects. The fimbria oviduct protein could interact with the ovulated egg as a prerequisite to association with a slightly modified form, which then facilitates fertilization and embryonic development-reproductive processes occurring in the ampulla oviduct. The segmental and temporal secretory specialization of the oviduct during pregnancy is a biological phenomenon that would promote reproductive success.
As expected, the isthmus oviduct did not synthesize and release the Mr 90 000-92 000 glycoprotein at any stage of pregnancy examined. These findings extend and confirm our previous data on steroid-treated sheep [2] . We hypothesize that this protein enhances gamete interactions and early cleavage by associating with the oocyte and the embryo. Since the isthmus is a site for sperm storage and maturation [26] , it is not surprising that its biosynthetic activity differs from that of the fimbria and ampulla. These data show that only those regions of the oviduct that participate in either egg transport or egg-sperm interactions synthesize and release the Mr 90 000-92 000 protein.
In summary, the studies described here have shown that the sheep oviduct undergoes biosynthetic changes in a temporally and regionally specific manner during the first few days of pregnancy. An E-induced Mr 90 000-92 000 glycoprotein was synthesized and released by the fimbria and ampulla oviducts at a time that correlated with retrieval of the ovulated egg, fertilization, and embryonic development until the embryo reached the uterus. These biosynthetic alterations occurred while the oviduct was predominantly under the influence of E and before the rise in nidatory P. Data from other laboratories have shown that this Mr 90 000-92 000 glycoprotein provides part of the microenvironment of the embryo by coating the zona pellucida and embryonic membranes and entering the perivitelline space [8, 9] . In several species, including sheep and humans, in vitro fertilization rates are enhanced [27] and significant in vitro embryo growth occurs [12] [13] [14] in the presence of oviductal secretions. In recent years, substantial progress has been made in the development of procedures for in vitro fertilization and embryo culture. However, the success rates remain disappointingly low in humans and other animals. Detailed knowledge of oviduct-derived, steroid-regulated macromolecules, and of their contribution to gamete interactions and embryo cleavage, may lead to further significant improvements in the effort to maximize in vitro fertilization rates as well as subsequent embryo production and viability in humans and domestic farm animals.
